Articles on Fuzeon

Experimental Fusion Inhibitor TRI-1144 May Permit Less Frequent Dosing and Cause Fewer Injection Site Reactions than Enfuvirtide (Fuzeon) - 9/15/08

Patients with Multidrug-resistant HIV Achieve Good Results after Switching from Enfuvirtide (Fuzeon) to Raltegravir (Isentress) - 7/15/08

Effect of Enfuvirtide (Fuzeon) on Adherence to and Efficacy of Antiretroviral Therapy - 2/26/08

Roche and Trimeris to Discontinue "Biojector 2000" Device for Enfuvirtide (Fuzeon) - 10/05/07

Baseline Darunavir Sensitivity Does Not Predict Response to Boosted Ritonavir plus Enfuvirtide in Triple-class-experienced Patients: BLQ Study Final Results - 9/26/07

Safety and Efficacy of Enfuvirtide (Fuzeon) in Children with HIV - 9/11/07

High Response Rate with Enfuvirtide (Fuzeon) Plus Darunavir (Prezista) Regardless of Existing Protease Inhibitor Resistance - 8/07/07

Resistance to Enfuvirtide Does Not Affect Susceptibility to Other Classes of Entry Inhibitors   - 2/09/07

FDA Announces Changes to Enfuvirtide and Efavirenz Product Labels 2/06/07

[P45] Treatment of antiretroviral experienced, enfuvirtide naive, advanced HIV patients with a boosted tipranavir / enfuvirtide based regimen in clinical practice: 24-week results of an Italian cohort 11/27/06

[P184] Prospective study assessing injection site reactions, quality of life and enfuvirtide administration preference using Biojector versus needles 11/27/06

P205] Lack of virologic response to the combination of tipranavir/ritonavir + enfuvirtide in treatment experienced HIV-infected persons with multi-drug resistant virus can be predicted by the presence of two or more of six mutations from five positions in protease 11/27/06

[P183] Injection site reactions (ISR) and success of HAART influence continued use of enfuvirtide (T20) 11/27/06

[P30] A pilot 48 week study of once daily (180mg QD) vs twice daily (90mg BID) enfuvirtide (ENF) 11/27/06

[P47] Enfuvirtide + NRTIs for the treatment of HIV infected patients with concurrent active mycobacterial infection: a pilot experience 11/27/06

[P40] Inter-country variation in physician perspectives of enfuvirtide (ENF) prescribing 11/27/06

What is Fuzeon?

• Fuzeon is an anti-HIV medication. It is in a category of HIV medicines called fusion inhibitors, or more broadly, entry inhibitors.

• Fuzeon binds to a protein on HIV's surface called gp41. Once it does this, HIV cannot successfully bind with the surface of T-cells, thus preventing the virus from infecting healthy cells.

• Fuzeon will most likely need to be used in combination with other anti-HIV drugs.

What is the most important information I should know about Fuzeon?

• Fuzeon is a fusion inhibitor being manufactured by Trimeris and Hoffmann-La Roche. It was approved by the U.S. Food and Drug Administration (FDA) in March, 2003. Fuzeon is approved for HIV-positive people who have tried other anti-HIV drugs in the past and are unable to keep their viral loads undetectable using drugs that are currently available. It has not yet been approved for HIV-positive people who are starting anti-HIV drug treatment for the first time.

• Fuzeon must be used in combination with other anti-HIV drugs.

Safety Information / Side Effects

FUZEON indication:

FUZEON in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced patients. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in controlled studies of FUZEON of 24 weeks' duration. Subjects enrolled were treatment-experienced adults with evidence of HIV-1 viral replication despite ongoing antiretroviral therapy. There are no studies of FUZEON in antiretroviral-naïve patients. At present, there are no results from controlled clinical trials evaluating the effect of FUZEON on clinical progression of HIV-1.


Injection Site Reactions

FUZEON can cause injection site reactions.
Almost all people get injection site reactions with FUZEON.Reactions are usually mild to moderate but occasionally may be severe. Reactions on the skin where FUZEON is injected include:

itching
swelling
redness
pain or tenderness
hardened skin
bumps

These reactions usually happen within the first week of FUZEON treatment and can happen again as you keep using FUZEON. A reaction at one skin injection site usually lasts for less than 7 days. Injection site reactions may be worse when injections are given again in the same place on the body, or when the injection is given deeper than it should be (for example, into the muscle). If you are worried about the reaction you are having, call your healthcare provider to help you decide if you need medical care. If the injection site reaction you are having is severe, call your healthcare provider right away. If you have an injection site reaction, you can discuss with your healthcare provider ways to help the symptoms. An injection site can get infected. It is important to follow the FUZEON Injection Instructions to lower your chances of getting an injection site infection. Call your healthcare provider right away if there are signs of infection at the injection site such as oozing, increasing heat, swelling, redness or pain.